登录新浪财经APP 搜索【信披】查看更多考评等级 重要内容提示: ● 截止本公告日，中珠医疗控股股份有限公司（以下简称"中珠医疗"或"公司"）股东广州云鹰资本管理 有限公司（以下简称"云鹰资本"）持有公司无限售流通股106,821,844股，占公司总股本的5.36%。 ● 本次累计解除质押股份数量合计100,000,000股（分二笔解除质押），占其持有公司股份总数的 93.61%，占公司总股本的5.02%。 ● 本次股份解除质押后，云鹰资本剩余被质押股份数量为0。 中珠医疗于2026年1月22日收到5%以上股东云鹰资本送达的《中国证券登记结算有限责任公司解除证券 质押登记通知》，公司持股5%以上股东云鹰资本质押股份办理了股权质押登记解除手续。具体情况如 下： 一、上市公司股份解除质押基本情况 1、股份解除质押情况 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 ■ 注：本公告中若存在尾数差，均为四舍五入原因所致。 本次解除质押股份后，云鹰资本无后续质押计划，如云鹰资本未来进行股份质押，公司将根据后续质押 进展情 ...

证券代码：600568 证券简称：ST 中珠 公告编号：2026-003 号 | 股东名称 | 广州云鹰资本管理有限公司 | | --- | --- | | （1）第一笔解除质押情况 | | | 本次解除质押股份 | 50,000,000 | | 占其所持股份比例 | 46.81% | | 占公司总股本比例 | 2.51% | | 解除质押时间 | 2026 年 1 月 20 日 | | （2）第二笔解除质押情况 | | 1、股份解除质押情况 截止本公告日，中珠医疗控股股份有限公司（以下简称"中珠医疗"或"公司"） 股东广州云鹰资本管理有限公司（以下简称"云鹰资本"）持有公司无限售流通 股 106,821,844 股，占公司总股本的 5.36%。 本次累计解除质押股份数量合计 100,000,000 股（分二笔解除质押），占其持有 公司股份总数的 93.61%，占公司总股本的 5.02%。 本次股份解除质押后，云鹰资本剩余被质押股份数量为 0。 中珠医疗控股股份有限公司 关于公司持股 5%以上股东股份解除质押的公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并 ...

南财智讯1月22日电，ST中珠公告，公司于2026年1月22日收到持股5%以上股东广州云鹰资本管理有限 公司送达的《中国证券登记结算有限责任公司解除证券质押登记通知》，云鹰资本所持公司股份合计 100,000,000股办理了股权质押登记解除手续。本次累计解除质押股份数量合计1.00亿股，占其持有公司 股份总数的93.61%，占公司总股本的5.02%。本次股份解除质押后，云鹰资本剩余被质押股份数量为 0。 ...

Market Overview - The medical services sector experienced a decline of 0.25% on January 22, with Chengda Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4122.58, up 0.14%, while the Shenzhen Component Index closed at 14327.05, up 0.5% [1] Stock Performance - Notable gainers in the medical services sector included: - Yinos (688710) with a closing price of 66.35, up 5.96% [1] - Hite Bio (300683) at 30.94, up 4.28% [1] - Puri Eye (301239) at 34.79, up 3.73% [1] - Conversely, significant decliners included: - Chengda Pharmaceutical (301201) at 39.67, down 4.16% [2] - Nanmo Bio (688265) at 48.21, down 3.17% [2] - Pruis (301257) at 66.99, down 2.63% [2] Capital Flow - The medical services sector saw a net outflow of 313 million yuan from institutional investors, while retail investors experienced a net inflow of 89.45 million yuan [2] - The capital flow for specific stocks showed: - Innovation Medical (002173) had a net inflow of 89.74 million yuan from institutional investors [3] - Kanglong Chemical (300759) saw a net inflow of 44.95 million yuan from institutional investors [3] - Chengda Pharmaceutical (301201) had a net outflow of 20.46 million yuan from retail investors [3]

Core Insights - The launch of "Jinbiao Niu Light Flavor Baijiu" by Niulanshan Distillery reflects a strategic response to evolving consumer preferences towards healthier and more enjoyable drinking experiences, showcasing the company's market sensitivity and innovation capabilities [1][5] - The Chinese baijiu industry is undergoing a significant structural transformation, shifting from scale expansion to quality and value enhancement, driven by generational changes in consumer demographics and preferences [1][4] Product Innovation - "Jinbiao Niu Light Flavor Baijiu" is a low-alcohol (36% vol) pure grain liquor that achieves a balanced flavor profile through scientific adjustments in its flavor substance system, offering a smooth drinking experience [1][2] - The product's formulation includes a unique blend of five grains: 42% sorghum, 26% rice, 16% glutinous rice, 10% wheat, and 6% corn, which aligns closely with the golden ratio, enhancing its flavor complexity [2][3] - Advanced brewing techniques, such as low-temperature fermentation extended from 60 days to 95 days, and multi-stage precision separation technology, contribute to the product's smoothness and purity, setting a new quality benchmark in the low-alcohol baijiu segment [3][4] Market Trends - The younger generation of consumers is shifting the value definition of baijiu from social settings to personal experiences, emphasizing flavor, health, emotional resonance, and cultural identity [4][5] - "Jinbiao Niu Light Flavor Baijiu" is designed to be versatile, suitable for both neat consumption and as a base for cocktails, catering to diverse drinking scenarios such as social gatherings and personal enjoyment [4][5]

证券代码：600568 证券简称：ST 中珠 公告编号：2026-002 号 中珠医疗控股股份有限公司 关于补选第十届董事会各专门委员会委员的公告 特别提示 2026 年 1 月 5 日，公司召开第十届董事会第十六次会议，审议通过《关于 补选第十届董事会各专门委员会委员的议案》。 经公司董事长提名，董事会同意补选独立董事郑颖怡女士为战略委员会委 员、审计委员会委员、提名委员会委员、薪酬与考核委员会委员。郑颖怡女士 具有注册会计师从业资格，为会计专业人士，董事会同意选举郑颖怡女士担任 审计委员会召集人。 经公司董事长提名，董事会同意补选董事房巍屹女士为审计委员会委员、 薪酬与考核委员会委员；同意补选董事刘会平先生为提名委员会委员。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 中珠医疗控股股份有限公司（以下简称"中珠医疗"或"公司"）董事会于 2026 年 1 月 5 日召开第十届董事会第十六次会议，审议通过《关于补选第十届 董事会各专门委员会委员的议案》，现将具体情况公告如下： 一、董事离任及补选情况 2025 年 11 月 ...

证券代码：600568 证券简称：ST 中珠 公告编号：2026-001 号 中珠医疗控股股份有限公司 第十届董事会第十六次会议决议公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 二、董事会会议审议情况 经与会董事认真审议，通过以下议案： （一）审议通过《关于补选第十届董事会各专门委员会委员的议案》； 表决结果：同意 9 票，反对 0 票，弃权 0 票。 经公司董事长提名，董事会同意补选独立董事郑颖怡女士为战略委员会委 员、审计委员会委员、提名委员会委员、薪酬与考核委员会委员。郑颖怡女士 具有注册会计师从业资格，为会计专业人士，董事会同意选举郑颖怡女士担任 审计委员会召集人。 经公司董事长提名，董事会同意补选董事房巍屹女士为审计委员会委员、 薪酬与考核委员会委员；同意补选董事刘会平先生为提名委员会委员。 1、中珠医疗控股股份有限公司（以下简称"中珠医疗"或"公司"）第十 届董事会第十六次会议的召开符合有关法律、行政法规、部门规章、规范性文 件和《公司章程》的规定。 2、本次董事会会议于 ...

Group 1: Industry Recovery and Trends - In 2025, China's venture capital industry emerged from a two-year downturn, showing signs of recovery across the entire investment chain, driven by a combination of funding and project highlights, as well as supportive policies [1] - The year-end activities of venture capitalists indicate a strong return to the industry, fueled by a new wave of technological changes and ongoing policy benefits [1] Group 2: Government Investment Fund Policies - The State Council issued a significant document aimed at promoting the high-quality development of government investment funds, focusing on stricter controls on new fund establishments and optimizing investment policies [2] - Various local governments have responded by issuing supporting policy documents, further regulating the operation of government investment funds to promote high-quality industry development [2] Group 3: Banking Sector Involvement - Since the announcement of expanded pilot programs for bank-affiliated financial asset investment companies (AICs), banks have accelerated their entry into the primary market, with several major banks successfully establishing AICs [3] - As of now, AICs from six major state-owned banks and three national joint-stock banks have been established, with total investments reaching 45.272 billion yuan, a year-on-year increase of approximately 37.7% [3] Group 4: Special Bonds for Government Guidance Funds - Several local governments have issued special bonds to support government guidance funds, breaking the previous norm that prohibited such investments [4] - A total of 52 billion yuan in special bonds have been issued by nine provinces and cities, significantly enhancing the funding pool for the venture capital industry [4] Group 5: Long-Term Government Guidance Funds - New government guidance funds established this year have extended their duration beyond the typical 10 years, with some lasting up to 20 years, providing long-term support for projects [5] - This trend of extending fund durations is expected to create a more patient investment environment, allowing for better exit strategies [5] Group 6: Mergers and Acquisitions - The introduction of policies supporting private equity funds in acquiring listed companies has led to a surge in related acquisition cases, with several venture capital firms actively pursuing stakes in public companies [6][7] - The trend of startups acquiring listed companies is also on the rise, indicating a new strategy for both startups and venture capital firms to explore exit routes [7] Group 7: Domestic PE Firms Acquiring Foreign Brands - Domestic top-tier private equity firms have increasingly acquired the Chinese operations of overseas consumer brands, highlighting a trend of local capital participating in the localization of foreign brands [8] - This trend is driven by the combination of ample funding, local operational expertise, and the stable cash flow of established foreign brands [8] Group 8: Technology Innovation Bonds - The introduction of technology innovation bonds has opened new fundraising channels for venture capital institutions, with several private firms successfully issuing bonds at competitive interest rates [9] - The issuance of these bonds has significantly boosted market confidence and marked a transition towards a more normalized support phase for private venture capital institutions [9] Group 9: Mainland VC/PE Expansion into Hong Kong - Several mainland investment institutions have established offices in Hong Kong, attracted by the region's supportive environment for technological innovation [10] - The Hong Kong government's initiatives, including the establishment of a significant innovation and technology fund, have further encouraged mainland VC/PE firms to expand into the market [10] Group 10: Return of Dollar LPs to China - Multiple venture capital firms have successfully raised dollar-denominated funds, indicating a renewed interest from international investors in the Chinese market [11][12] - The return of dollar LPs coincides with the rapid growth of China's AI industry, highlighting the potential undervaluation of Chinese assets [11][12] Group 11: National Entrepreneurship Investment Fund - The establishment of a "carrier-level" national entrepreneurship investment fund aims to support startups across key economic regions in China, with a focus on early-stage investments [13] - This fund features a long duration of 20 years and aims to provide substantial financial backing to venture capital institutions and startups, enhancing the overall investment landscape [13]

重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一) 股东会召开的时间：2025 年 12 月 25 日 证券代码：600568 证券简称：ST 中珠 公告编号：2025-070 号 中珠医疗控股股份有限公司 2025年第四次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (五) 公司董事和董事会秘书的列席情况 1、公司在任董事7人，列席4人，董事戴绍宏先生、董事盛剑明先生、独立董事 栗胜男女士因公务未能出席本次会议； 2、董事长陈旭先生暂代董事会秘书职务并出席会议；总裁麻华先生、副总裁刘 会平先生、副总裁司培超先生、财务总监谭亮先生列席本次会议。 二、 议案审议情况 (一) 累积投票议案表决情况 1、 《关于补选公司第十届董事会非独立董事候选人的议案》 (二) 股东会召开的地点：珠海市情侣南路 1 号仁恒滨海中心 5 座 8 层 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 186 | | --- | --- | | ...

北京德恒（深圳）律师事务所 关于中珠医疗控股股份有限公司 2025年第四次临时股东会的 法律意见 北京德恒律师事务所 DeHeng Law Offices 深圳市福田区金田路 4018 号安联大厦 B 座 11 层 电话:0755-88286488 传真:0755-88286499 邮编:518026 北京德恒(深圳)律师事务所 关于中珠医疗控股股份有限公司 2025 年第四次临时股东会的法律意见 北京德恒(深圳)律师事务所 关于中珠医疗控股股份有限公司 2025年第四次临时股东会 的法律意见 德恒 06G20250412-01 号 致:中珠医疗控股股份有限公司 中珠医疗控股股份有限公司(以下简称"公司")2025 年第四次临时股东 会(以下简称"本次会议")于 2025年12月25日(星期四)召开。北京德恒 (深圳)律师事务所(以下简称"德恒"或"本所")受公司委托,指派邓宇戈 律师、李艾岭律师(以下简称"本所律师")出席了本次会议。根据《中华人民 共和国证券法》(以下简称"《证券法》")、《中华人民共和国公司法》(以 下简称"《公司法》")、中国证券监督管理委员会《上市公司股东会规则》(以 下简称"《股东 ...